StemCell Therapy

Ligand Pharmaceuticals Inc. (LGND) is around the top of the Biotechnology industry according to InvestorsObserver. LGND received an overall rating of 77, which means that it scores higher than 77 percent of all stocks. Ligand Pharmaceuticals Inc. also achieved a score of 90 in the Biotechnology industry, putting it above 90 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ligand Pharmaceuticals Inc. (LGND) stock is lower by -3.25% while the S&P 500 is up 1.19% as of 1:47 PM on Wednesday, Aug 12. LGND is down -$3.64 from the previous closing price of $111.90 on volume of 172,921 shares. Over the past year the S&P 500 has risen 15.28% while LGND is up 15.11%. LGND lost -$1.38 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Ligand Pharmaceuticals Inc. click here.

Read the rest here:
Is Ligand Pharmaceuticals Inc. (LGND) the Top Pick in the Biotechnology Industry? - InvestorsObserver

This entry was posted on August 12, 2020 at 8:48 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |